Quizartinib for Newly Diagnosed <i>FLT3</i> -Internal Tandem Duplication–Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI StudyPau Montesinos, Jorge Labrador, Teresa Bernal et al.|Journal of Clinical Oncology|2025Cited by 13
Final Results of Quiwi: A Double Blinded, Randomized Pethema Trial Comparing Standard Chemotherapy Plus Quizartinib Versus Placebo in Adult Patients with Newly Diagnosed <i>FLT3</i>-ITD Negative AMLPau Montesinos, Jorge Labrador, Rebeca Rodríguez‐Veiga et al.|Blood|2024Cited by 5
Clinical impact of FLT3 microclones on outcomes in patients with newly diagnosed FLT3-ITD negative AML: A subanalysis from the pethema quiwi trialClaudia Sargas, Pau Montesinos, Augustin Boudry et al.|Blood|2025Cited by 3